



**BAISHIDENG PUBLISHING GROUP INC**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com <http://www.wjgnet.com>

---

**Name of Journal:** *World Journal of Cardiology*

**ESPS Manuscript NO:** 23941

**Manuscript Type:** Review

Josef Finsterer, MD, PhD  
KAR  
1030 Vienna  
Austria, Europe  
Tel. +43-1-71165-92085  
Fax. +43-1-4781711  
Email: fipaps@yahoo.de

To:  
Editor in Chief  
World J Cardiol

Manuscript: 23941  
"Mitochondrial vasculopathy"

Dear Prof. Qiu,

Thank you for your email dating 16th February 2016 and your and the reviewer's valuable comments concerning the above mentioned manuscript. We revised the manuscript according to these suggestions with particular regard to the following points:

**Reviewer 211908:**

PP 2: Line 2: MIMODS: please mention this abbreviation full out for the first time.  
Was written in full at first occurrence.

PP 2: Line 10: please consider "leukoencephalopathy" instead of "leucencephalopathy".  
You may use leukoencephalopathy throughout the manuscript.  
Was changed as suggested

PP 2: Line 16: please consider "macroangiopathy" instead of "microangiopathy".  
Was changed as suggested.

PP 4: Line 2: Were only 20 (XX) papers identified as suitable to be discussed in this review?

Thank you. The figure was changed to 59.

PP 4: Line 3: various or different is redundant, you may chose one of these two words.

Thank you. Was changed as suggested.

PP 4: Lines 11 and 12: various or different is redundant, you may chose one of these two words.

Thank you. Was changed as suggested.

PP 4: Line 17: please clarify the abbreviation VSMCs.

Was written in full.

PP 4: Line 22: MELAS: please mention this abbreviation full out for the first time like "Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes".

General suggestion to summarize the features of each type to facilitate easy readability.

All acronyms were written in full at first occurrence

PP 9: Line 10: please check the number of patients reported from reference [49].

The number of investigated patients was 10.

PP 9: Line 12: any news about acceptance of the submission of [Finsterer et al].

Was changed to “personal communication” since it is still not accepted.

PP 12: Line 9: please clarify the abbreviation SLEs.

Was written in full

Reviewer 214291:

Interesting review presenting a good analysis of mitochondrial vasculopathy.

Thank you for this comment.

**Reviewer 227341:**

PP2, line 11 please consider” leukoencephalopathy” or “ Mitochondrial encephalomyopathy” instead of leucencephalopathy. You may use leukoencephalopathy” or “ Mitochondrial encephalomyopathy” throughout the paper.

Was changed as suggested.

PP2, line 19 please use macroangiopathy instead of microangiopathy

Was changed as suggested.

PP4, line 16 please specify the abbreviation VSMCs

Was provided

PP4 line 22 please specify MELAS syndrome” Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome” and its clinical manifestations

Was changed as suggested

PP5, line 35 please specify the acronym FLAIR (Fluid Attenuated Inversion Recovery)

Was provided as suggested.

PP6, line 4 please specify the abbreviation HMPAO-SPECT using 99mTc-hexamethylpropyleneamine oxime single-photon emission CT . You may use 99mTc-HMPAO SPECT throughout the paper.

Was changed as suggested.

PP11, line 2 please specify the abbreviation SLEs

Was provided

We hope that the changes made adequately meet all points raised by the reviewer and hereby re-submit the revised manuscript for publication in the “World J Cardiol”.

The manuscript has not been published, submitted or is not simultaneously being submitted elsewhere, and no portion of the data has been or will be published in proceedings or transactions of meetings or symposium volumes. There is no financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interest of the authors, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work. Both authors approved submission of the manuscript.

Please confirm receipt of the manuscript.

Sincerely Yours,

J. Finsterer, MD, PhD

Vienna, 23rd February. 2016